Development of resistance to 5-fluorocytosine in Candida parapsilosis during therapy.
D000328:Adult; D000619:Aminohydrolases / Q000378:metabolism; D000666:Amphotericin B / Q000627:therapeutic use; D000935:Antifungal Agents / Q000627:therapeutic use*; D002175:Candida / Q000187:drug effects / Q000201:enzymology; D002177:Candidiasis / Q000188:drug therapy* / Q000209:etiology; D002474:Cell-Free System; D003596:Cytosine / Q000627:therapeutic use*; D004352:Drug Resistance, Microbial; D004696:Endocarditis / Q000188:drug therapy* / Q000209:etiology; D005260:Female; D005437:Flucytosine / Q000627:therapeutic use; D006556:Heroin Dependence / Q000150:complications; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use; D012008:Recurrence; D014320:Triphenylmethyl Compounds / Q000627:therapeutic use
D000935:Antifungal Agents; D007093:Imidazoles; D014320:Triphenylmethyl Compounds; D000666:Amphotericin B; D003596:Cytosine; D005437:Flucytosine; D000619:Aminohydrolases